Cyclerion licenses MIT tech for treatment-resistant depression; relaunches as neuropsychiatry company

Cyclerion Therapeutics, Inc.

Entered exclusive worldwide license with MIT for neuropsychiatric technology; upfront payment nominal, milestones up to $4.4M plus low single-digit royalties.
Lead program targets 3M Americans with treatment-resistant depression (TRD); Phase 2 proof-of-concept trial expected to start 2026 with data in 2027.
Company relaunches as innovation-driven neuropsychiatry firm, led by world-class team in neuropsychiatry, anesthesiology, and machine learning.
Expanding pipeline beyond TRD; exploring therapies for other neuropsychiatric diseases with large unmet needs.

item 1.01item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.